GXAI
Gaxos.ai Inc.1.0900
+0.0000+0%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
7.76MP/E (TTM)
-Basic EPS (TTM)
-0.39Dividend Yield
0%Recent Filings
10-Q
10-Q
Q2 FY2025 results
Gaxos.ai posted Q2 revenue of $171K, up from zero a year ago, driven by RNK Health's administrative services supporting telehealth patient care, while in-game items and subscriptions added minor contributions. Operating loss widened to $983K from $855K y/y, fueled by marketing pushes for health initiatives, yet offset by steady R&D at $243K; net loss narrowed to $825K, or $0.11 per share on 7.1M diluted shares, thanks to $158K in interest and investment gains. Cash dipped to $1.7M with $12.3M in short-term investments, but working capital stands at $14M after a $748K software buy blending cash and stock. Free cash flow not disclosed in the 10-Q. Telehealth rules pose regulatory hurdles.
8-K
Annual meeting elects board, ratifies auditor
Gaxos.ai Inc. held its 2025 annual stockholder meeting on August 12, electing Vadim Mats, Adam Holzer, Scott Grayson, and Roman Feldman to the board with strong support, though broker non-votes hit 1.9 million shares. Stockholders ratified Salberg & Company as auditors for the fiscal year ending December 31, 2025, with 2.3 million votes in favor. They also approved boosting the 2022 Omnibus Equity Incentive Plan's share reserve to 803,637 from 553,637, signaling room for more incentives. Yet continuity rules the day.
10-Q
Q1 FY2025 results
Gaxos.ai posted Q1 FY2025 revenue of $23,732, up sharply from $19 a year ago, driven by $22,552 from RNK Health's non-clinical administrative services while in-game items and subscriptions added modest amounts. Operating expenses climbed 35.6% to $1,415,427, fueled by higher R&D and marketing for health platforms, yielding an operating loss of $1,391,695 versus $1,043,839 last year; net loss narrowed to $1,232,062 from $912,145, thanks to $159,633 in interest and investment gains, with EPS improving to $(0.17) on 7,001,231 diluted shares. Cash dipped to $2.57M from $14.40M after $10.53M in short-term investments, but $12.12M in those plus $14.67M working capital signal stability. In February 2025, it closed a software buy for $500,000 cash and 200,000 shares, recognizing $748,000 in intangibles amortized over 5 years. Yet regulatory shifts could crimp RNK Health's telehealth partnerships.
10-K
FY2024 results
Gaxos.ai Inc. posted FY2024 revenue of $4,027, a sharp rise from $256 in FY2023, driven by nascent health coaching sales amid ongoing product launches in AI gaming and wellness tools. Yet, the company deepened its net loss to $3.42 million from $3.95 million, as operating expenses fell 7.7% to $3.71 million, with R&D up 8.8% on Gaxos Health development while G&A dipped on lower stock-based comp. Q4 momentum showed sequential user growth in proprietary games like Space Striker AI, but no quarterly breakdowns were disclosed; cash swelled to $14.4 million via equity raises, funding runway through 2025 without debt. No annual guidance emerged, though expansion into GLP-1 meds via RNK Health hints at Q1 acceleration. Cyber risks loom large, potentially stalling quarterly tech rollouts.
IPO
Website
Employees
Sector
Industry
DKI
DarkIris Inc.
0.37-0.03
EA
Electronic Arts Inc.
204.20+0.00
GAME
GameSquare Holdings, Inc.
0.51+0.02
GCL
GCL Global Holdings Ltd
1.13+0.01
GDC
GD Culture Group Limited
3.60-0.10
GDEV
GDEV Inc.
16.07+0.02
GLAI
Global AI Inc.
0.85+0.00
GMGI
Golden Matrix Group, Inc.
0.82+0.03
MGAM
Mobile Global Esports Inc.
0.15+0.03
RBLX
Roblox Corporation
87.44+0.48